← United States · Coverage record
US · SEC FORM 4
Merus N.V.
MRUS · — · CIK 0001651311 · Healthcare
INSIDER SIGNAL
0 qualifying P purchase groups
in the current 180-day scoring window
0 Form 4 transaction lines observed in the same window
0 sales · 0 option, withholding, award, gift or other lines
WHY NO ACTIVE SIGNAL?
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Purchase breadth, concentration & cluster buying
These modules activate when qualifying purchases enter the 180-day research window.
Insider activity timeline
No Form 4 transaction event is present in the current 180-day window.
SIGNAL HISTORY
Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2025-12-29 · GENMAB A/S.
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.
Short interest
The FINRA report lists no short interest for this ticker.
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2025-12-29 | GENMAB A/S | Purchase (P) | Common Shares, nominal value EUR 0.09 per share | 76,920,005 | USD 97.00 | USD 7,461,240,485 | SEC filing ↗ |
| 2025-12-26 | GENMAB A/S | Purchase (P) | Common Shares, nominal value EUR 0.09 per share | 2,978 | USD 97.00 | USD 288,866 | SEC filing ↗ |
| 2025-12-26 | GENMAB A/S | Purchase (P) | Common Shares, nominal value EUR 0.09 per share | 142,610 | USD 97.00 | USD 13,833,170 | SEC filing ↗ |
| 2025-12-24 | GENMAB A/S | Purchase (P) | Common Shares, nominal value EUR 0.09 per share | 96,082 | USD 97.00 | USD 9,319,954 | SEC filing ↗ |
| 2025-12-23 | GENMAB A/S | Purchase (P) | Common Shares, nominal value EUR 0.09 per share | 561,042 | USD 97.00 | USD 54,421,074 | SEC filing ↗ |
| 2025-12-22 | GENMAB A/S | Purchase (P) | Common Shares, nominal value EUR 0.09 per share | 15,710 | USD 97.00 | USD 1,523,870 | SEC filing ↗ |
| 2025-12-19 | GENMAB A/S | Purchase (P) | Common Shares, nominal value EUR 0.09 per share | 66,264 | USD 97.00 | USD 6,427,608 | SEC filing ↗ |
| 2025-12-18 | GENMAB A/S | Purchase (P) | Common Shares, nominal value EUR 0.09 per share | 212,177 | USD 97.00 | USD 20,581,169 | SEC filing ↗ |
| 2025-12-17 | GENMAB A/S | Purchase (P) | Common Shares, nominal value EUR 0.09 per share | 150,795 | USD 97.00 | USD 14,627,115 | SEC filing ↗ |
| 2025-12-16 | GENMAB A/S | Purchase (P) | Common Shares, nominal value EUR 0.09 per share | 120,752 | USD 97.00 | USD 11,712,944 | SEC filing ↗ |
| 2022-11-03 | Lundberg Sven Ante | Purchase (P) | Common Shares | 14,706 | USD 14.38 | USD 211,472 | SEC filing ↗ |
| 2022-08-22 | Lundberg Sven Ante | Purchase (P) | Common Stock | 5,826 | USD 22.92 | USD 133,532 | SEC filing ↗ |
| 2022-08-19 | Lundberg Sven Ante | Purchase (P) | Common Stock | 704 | USD 22.99 | USD 16,185 | SEC filing ↗ |
| 2022-07-12 | Lundberg Sven Ante | Purchase (P) | Common Shares | 4,340 | USD 22.97 | USD 99,690 | SEC filing ↗ |
| 2021-03-30 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | Purchase (P) | Common Shares, (euro)0.09 nominal value per share | 300,000 | USD 19.75 | USD 5,925,000 | SEC filing ↗ |
Form 4 evidence
34 transaction lines in the latest 365-day window; 209 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2025-12-29 | GENMAB A/S | Purchase (P) | Common Shares, nominal value EUR 0.09 per share | 76,920,005 | USD 97.00 | USD 7,461,240,485 | SEC filing ↗ |
| 2025-12-26 | GENMAB A/S | Purchase (P) | Common Shares, nominal value EUR 0.09 per share | 2,978 | USD 97.00 | USD 288,866 | SEC filing ↗ |
| 2025-12-26 | GENMAB A/S | Purchase (P) | Common Shares, nominal value EUR 0.09 per share | 142,610 | USD 97.00 | USD 13,833,170 | SEC filing ↗ |
Show recent Form 4 evidence (18 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2025-12-29 | GENMAB A/S | Purchase (P) | Common Shares, nominal value EUR 0.09 per share | 76,920,005 | USD 97.00 | USD 7,461,240,485 | SEC filing ↗ |
| 2025-12-26 | GENMAB A/S | Purchase (P) | Common Shares, nominal value EUR 0.09 per share | 2,978 | USD 97.00 | USD 288,866 | SEC filing ↗ |
| 2025-12-26 | GENMAB A/S | Purchase (P) | Common Shares, nominal value EUR 0.09 per share | 142,610 | USD 97.00 | USD 13,833,170 | SEC filing ↗ |
| 2025-12-24 | GENMAB A/S | Purchase (P) | Common Shares, nominal value EUR 0.09 per share | 96,082 | USD 97.00 | USD 9,319,954 | SEC filing ↗ |
| 2025-12-23 | GENMAB A/S | Purchase (P) | Common Shares, nominal value EUR 0.09 per share | 561,042 | USD 97.00 | USD 54,421,074 | SEC filing ↗ |
| 2025-12-22 | GENMAB A/S | Purchase (P) | Common Shares, nominal value EUR 0.09 per share | 15,710 | USD 97.00 | USD 1,523,870 | SEC filing ↗ |
| 2025-12-19 | GENMAB A/S | Purchase (P) | Common Shares, nominal value EUR 0.09 per share | 66,264 | USD 97.00 | USD 6,427,608 | SEC filing ↗ |
| 2025-12-18 | GENMAB A/S | Purchase (P) | Common Shares, nominal value EUR 0.09 per share | 212,177 | USD 97.00 | USD 20,581,169 | SEC filing ↗ |
| 2025-12-17 | GENMAB A/S | Purchase (P) | Common Shares, nominal value EUR 0.09 per share | 150,795 | USD 97.00 | USD 14,627,115 | SEC filing ↗ |
| 2025-12-16 | GENMAB A/S | Purchase (P) | Common Shares, nominal value EUR 0.09 per share | 120,752 | USD 97.00 | USD 11,712,944 | SEC filing ↗ |
| 2025-12-12 | Shuman Harry | U (U) | Common Shares | 11,002 | USD 97.00 | USD 1,067,194 | SEC filing ↗ |
| 2025-12-12 | Lundberg Sven Ante | U (U) | Common Shares | 65,052 | USD 97.00 | USD 6,310,044 | SEC filing ↗ |
| 2025-12-12 | Iwicki Mark T | U (U) | Common Shares | 73,576 | USD 97.00 | USD 7,136,872 | SEC filing ↗ |
| 2025-11-26 | Shuman Harry | Sale (S) | Common Shares | 1,700 | USD 96.10 | USD 163,370 | SEC filing ↗ |
| 2025-11-26 | Shuman Harry | Option exercise / conversion (M) | Common Shares | 1,700 | USD 21.69 | USD 36,875 | SEC filing ↗ |
| 2025-11-25 | Shuman Harry | Sale (S) | Common Shares | 8,300 | USD 95.92 | USD 796,136 | SEC filing ↗ |
| 2025-11-25 | Shuman Harry | Option exercise / conversion (M) | Common Shares | 7,300 | USD — | USD — | SEC filing ↗ |
| 2025-11-25 | Lundberg Sven Ante | Gift (G) | Common Shares | 160,834 | USD 0.00 | USD 0 | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-19 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | MRUS |
| CIK | 0001651311 |
| Sector | Healthcare |
| Industry | — Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| Exchange | — |
Data coverage
| Local Form 4 history | 209 transaction lines from 2020-01-02 to 2025-12-29 49 P purchase lines · 46 S sale lines · 114 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.